All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TB202-3
Therapeutic Area: Infections and Infectious Diseases Product Name: TB202-3
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
The data shows that TB202-3 and TB202-63, both single domain VHH “nanobodies,” protect against weight loss, a key indicator of disease severity, at the lowest dose of 1 mg/kg in a preclinical hamster challenge model.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CAR-T cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Neogene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 13, 2020
Details:
The companies will leverage Neogene’s expertise in targeting tumor neo-antigens, mutated proteins found in cancer cells together with Twist’s DNA synthesis platform and product lines to develop personalized CAR) T cell therapies and TCR therapies for patients with cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bispecific antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Seismic Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 04, 2020
Details:
Twist Biopharma will use Hyperimmune Libraries, two fully human antibody libraries focused on the heavy chain complementary determining region 3 (CDR3) loop diversity involved in antigen recognition, to identify antibodies that bind to the specified immuno-oncology targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anti-SARS-CoV-2 S1 Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
The Twist anti-SARS-CoV-2 S1 Antibody Panel includes 32 human antibodies that bind with picomolar to nanomolar affinity to S1 spike protein on the SARS-CoV-2 virus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibodies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Invetx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 16, 2020
Details:
Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will use its Twist Antibody Optimization (TAO) platform to engineer and optimize multiple antibodies against important disease targets in animal health.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
Details:
Under the pact Takeda will tap the Twist Bioscience's phage display libraries for the discovery, validation and optimization of antibodies in Takeda’s pipeline of biologics across its four core areas: oncology, rare diseases, neuroscience and gastroenterology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Neutralizing antibody therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Proteona
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
The international alliance was initiated by Proteona in response to the urgent need of patients most at risk facing the pandemic. The alliance aims to develop antibody therapies to provide a safe and targeted treatment for these vulnerable populations.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Synthetic genes
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vanderbilt University Medical Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 26, 2020
Details:
Twist Biopharma, will provide custom antibody drug discovery libraries and will screen the libraries for potential antibody therapeutics that would treat patients with COVID-19.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
